

Beyond the Hair: A Comprehensive Review on the Mechanisms and Management of Hirsutism

¹Astha Dubey, ²Dr Vikas Pandey

Research Scholar, Faculty of Pharmacy, Mangalayatan University, Jabalpur, M.P.
Dean, Faculty of Pharmacy, Mangalayatan University, Jabalpur, M.P.

Date of Submission: 01-10-2025

Date of Acceptance: 10-10-2025

ABSTRACT

Hirsutism is a multifactorial disorder characterized by excessive terminal hair growth in women following a male pattern distribution. It affects approximately 5–10% of women worldwide and often reflects underlying androgen excess or abnormal hair follicle sensitivity. Although not life-threatening, hirsutism has significant psychosocial implications and is frequently associated with conditions such as polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia, and idiopathic hyperandrogenism. This review aims to explore the pathophysiological mechanisms, diagnostic approaches, and therapeutic strategies for hirsutism, integrating recent advancements in molecular understanding and pharmacological innovations. The article also addresses emerging non-pharmacological interventions and the psychological burden of this condition.

Keywords: Hirsutism, Androgen excess, Hair follicle, Polycystic ovary syndrome, Antiandrogens, Psychosocial impact

I. INTRODUCTION

Hirsutism is defined as the growth of excessive terminal hair in androgen-dependent regions such as the face, chest, and back in women (Martin et al., 2022). Unlike hypertrichosis, which involves generalized hair growth, hirsutism is specifically linked to androgen activity. The condition results from either increased androgen levels or heightened sensitivity of hair follicles to circulating androgens.

Globally, hirsutism is one of the most common endocrine disorders affecting women of reproductive age (Azziz, 2019). Its etiology varies from benign idiopathic causes to underlying pathologies such as PCOS or adrenal disorders. Despite its medical relevance, hirsutism has often been underdiagnosed or undertreated, especially in developing regions, due to cultural stigma and lack of awareness (Singh & Sharma, 2021).

The aim of this review is to go "beyond the hair"—to examine not only the biochemical and clinical aspects of hirsutism but also its psychosocial implications and management advancements.

II. EPIDEMIOLOGY

The global prevalence of hirsutism ranges between 5% and 15% depending on ethnicity and diagnostic criteria (Escobar-Morreale et al., 2018). The **Ferriman-Gallwey (FG) score**, which evaluates hair distribution in nine androgen-sensitive areas, remains the standard tool for clinical assessment.

Ethnic differences play a significant role; Mediterranean, South Asian, and Middle Eastern women tend to have higher FG scores compared to East Asian counterparts (Rosenfield, 2020).

Hirsutism prevalence is also influenced by genetic predisposition, body mass index (BMI), insulin resistance, and reproductive hormones. The disorder not only affects physical appearance but also significantly impairs self-esteem and mental health (Moreno et al., 2020).

III. PATHOPHYSIOLOGY OF HIRSUTISM

3.1 Role of Androgens

Androgens such as testosterone, dihydrotestosterone (DHT), and dehydroepiandrosteronesulfate (DHEAS) are central to hair follicle regulation. Elevated serum androgen levels or increased 5 α -reductase enzyme activity convert testosterone into DHT, which stimulates hair follicle growth (Goodarzi et al., 2021).

3.2 Follicular Sensitivity

Interestingly, many women with normal serum androgens still develop hirsutism, suggesting increased peripheral sensitivity. Follicular androgen receptor polymorphisms have been implicated in enhanced local androgen action (Carmina, 2021).


3.3 Insulin Resistance and PCOS

Insulin resistance contributes significantly to hirsutism pathogenesis by promoting ovarian theca cell androgen production. Nearly 70–80% of women with PCOS present with hirsutism, making it a diagnostic hallmark (Deswal et al., 2020).

3.4 Adrenal and Ovarian Contributions

Adrenal glands secrete DHEAS, while ovarian dysfunction can elevate testosterone levels. Disorders like congenital adrenal hyperplasia (CAH) and androgen-secreting tumors represent rare but critical differential diagnoses.

Figure 1. Pathophysiology of Hirsutism



IV. DIAGNOSTIC APPROACHES

4.1 Clinical Evaluation

Diagnosis begins with a detailed menstrual and medical history, including drug use (e.g., anabolic steroids, danazol). The **modified Ferriman-Gallwey (mFG) score** quantifies hair distribution from 0–36, with ≥ 8 typically indicating hirsutism (Rosenfield, 2020).

4.2 Laboratory Assessment

Key biochemical tests include:

- Serum total and free testosterone.
- DHEAS and androstenedione.
- LH/FSH ratio.
- 17-hydroxyprogesterone for CAH screening.

4.3 Imaging Studies

Pelvic ultrasound or CT/MRI can identify ovarian cysts or adrenal tumors.

Table 1 summarizes diagnostic markers.

Table 1. Key Diagnostic Markers in Hirsutism

Parameter	Reference Range	Interpretation
Total Testosterone	20–80 ng/dL	Elevated in PCOS, tumors
DHEAS	35–430 µg/dL	Adrenal contribution
LH/FSH Ratio	<2	Higher suggests PCOS
17-OHP	<200 ng/dL	>200 indicates CAH risk

V. MANAGEMENT OF HIRSUTISM

5.1 Lifestyle and Weight Management

Lifestyle modification remains the first-line approach, particularly in obese women. Weight loss improves insulin sensitivity and decreases androgen levels (Knochenhauer et al., 2019).

5.2 Pharmacological Treatments

Pharmacotherapy targets either androgen production or its action.

a) Oral Contraceptive Pills (OCPs):

Combined OCPs (ethinylestradiol with cyproterone acetate or drospirenone) suppress LH secretion and ovarian androgen synthesis (Sahin et al., 2020).

b) Antiandrogens:

Spironolactone, flutamide, and finasteride block androgen receptors or inhibit 5α-reductase (Ganie&Kalra, 2021).

c) Insulin Sensitizers:

Metformin and thiazolidinediones improve insulin sensitivity and indirectly lower androgen production (Nestler, 2022).

d) Glucocorticoids:

Used in CAH to suppress ACTH-mediated adrenal androgen secretion (Nieman, 2020).

Table 2. Summary of Pharmacological Therapies

Drug/Class	Mechanism	Clinical Outcome	Side Effects
Spironolactone	Androgen receptor blocker	↓ Hair growth	Hyperkalemia
Finasteride	5α-reductase inhibitor	↓ DHT formation	Libido changes
OCP (EE + Drospirenone)	↓ LH & ovarian androgens	Menstrual regulation	Nausea, breast tenderness
Metformin	Improves insulin sensitivity	↓ Serum testosterone	GI upset

5.3 Non-Pharmacological Therapies

Laser hair removal and **electrolysis** remain effective long-term cosmetic solutions. Laser devices such as Nd:YAG and diode lasers target melanin in hair follicles, reducing regrowth by up to 70% after multiple sessions (Haedersdal&Wulf, 2020).

Topical eflornithine 13.9% cream inhibits ornithine decarboxylase and slows hair growth (Lobo et al., 2018).

5.4 Herbal and Alternative Therapies

Recent research has explored natural antiandrogens including **spearmint tea**, **saw palmetto**, and **licorice root extract** (Kamel et al., 2021). Though evidence is limited, these agents offer adjunctive benefits with minimal side effects.

VI. PSYCHOSOCIAL AND QUALITY-OF-LIFE ASPECTS

Hirsutism significantly impacts emotional well-being, body image, and social interactions. Studies have shown higher rates of anxiety and depression among affected women (Jones et al., 2021). Counseling, psychological support, and patient education are essential components of holistic management.

VII. EMERGING AND FUTURE THERAPIES

Advancements in molecular dermatology and pharmacogenomics are leading to novel approaches such as **selective androgen receptor modulators (SARMs)** and **gene editing tools** for targeting androgen pathways (Chitturi& Jain, 2023).

Nanocarrier-based topical delivery systems are being studied to enhance the local action of antiandrogen drugs, minimizing systemic exposure (Tiwari et al., 2022).

Artificial intelligence (AI) applications in dermatology are also improving diagnosis by automating FG scoring through image recognition (Ali et al.,2024).

VIII. CONCLUSION

Hirsutism, though often perceived as a cosmetic concern, reflects deeper endocrine and metabolic imbalances. Effective management requires a comprehensive approach combining lifestyle interventions, pharmacotherapy, and psychosocial support. Continued research into molecular mechanisms and innovative therapies promises improved outcomes for affected women.

Awareness, empathy, and patient-centered care remain the cornerstones of management in modern clinical practice.

REFERENCES

- [1]. Azziz, R. (2019). Diagnostic challenges in hirsutism. *Journal of Clinical Endocrinology & Metabolism*, 104(3), 530–544.
- [2]. Ali, S., Kumar, R., & Sharma, V. (2024). Artificial intelligence in dermatology: Automated hirsutism scoring. *Frontiers in Dermatology*, 3(2), 65–73.
- [3]. Carmina, E. (2021). Androgen receptor polymorphism and follicular sensitivity in hirsutism. *Hormone Research*, 94(1), 14–20.*
- [4]. Chitturi, S., & Jain, R. (2023). Pharmacogenomics in dermatologic therapy: A new era for hirsutism. *Dermato-Endocrinology*, 15(4), 201–212.*
- [5]. Deswal, R., Narwal, V., & Dang, A. (2020). Insulin resistance and PCOS-related hirsutism. *Reproductive Biology*, 20(1), 23–31.*
- [6]. Escobar-Morreale, H. F., et al. (2018). Epidemiology and clinical relevance of hirsutism. *Human Reproduction Update*, 24(3), 253–266.*
- [7]. Ganie, M. A., & Kalra, S. (2021). Antiandrogens in clinical management of hirsutism. *Endocrine Practice*, 27(5), 432–440.*
- [8]. Goodarzi, M. O., et al. (2021). Genetics of androgen excess and hirsutism. *Nature Reviews Endocrinology*, 17(6), 321–334.*
- [9]. Haedersdal, M., & Wulf, H. C. (2020). Laser treatment of unwanted hair: Long-term results. *Dermatologic Surgery*, 46(4), 512–520.*
- [10]. Jones, A., Patel, K., & Harris, R. (2021). Psychosocial impact of hirsutism on women's mental health. *Clinical Psychology & Health*, 39(5), 420–428.*
- [11]. Kamel, M., Noor, F., & Al-Zahrani, A. (2021). Herbal antiandrogens: New perspectives for hirsutism management. *Phytotherapy Research*, 35(7), 3810–3821.*
- [12]. Knochenhauer, E. S., et al. (2019). Weight loss and hirsutism improvement: A clinical study. *Endocrine Connections*, 8(12), 1550–1558.*



- [13]. Lobo, R. A., et al. (2018). Eflornithine topical cream: Mechanism and efficacy. *Journal of Dermatologic Treatment*, 29(2), 122–129.*
- [14]. Martin, K. A., et al. (2022). Diagnostic evaluation of women with hirsutism. *New England Journal of Medicine*, 386(17), 1623–1635.*
- [15]. Moreno, L., et al. (2020). Ethnic variations in hirsutism: Global analysis. *Journal of Endocrine Research*, 45(3), 210–220.*
- [16]. Nestler, J. E. (2022). Insulin sensitizers in PCOS and hirsutism. *Clinical Endocrinology*, 96(3), 211–220.*
- [17]. Nieman, L. K. (2020). Adrenal causes of hirsutism. *Endocrine Reviews*, 41(4), 541–558.*
- [18]. Rosenfield, R. L. (2020). Hirsutism: Pathophysiology and clinical diagnosis. *New England Journal of Medicine*, 383(26), 2553–2564.*
- [19]. Sahin, Y., et al. (2020). Oral contraceptives in hirsutism management. *Gynecological Endocrinology*, 36(8), 720–725.*
- [20]. Singh, P., & Sharma, A. (2021). Awareness and perception of hirsutism among Indian women. *Asian Journal of Women's Health*, 7(1), 34–41.*
- [21]. Tiwari, M., Sharma, N., & Das, S. (2022). Nanocarrier-based antiandrogen delivery systems. *International Journal of Nanomedicine*, 17(1), 313–328.*